• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
【24h】

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.

机译：多发性硬化症中干扰素-β治疗期间基质金属蛋白酶及其抑制剂的变化。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) play a key role in the pathogenesis of multiple sclerosis (MS) and have been proposed as biomarkers of response to therapy. We investigated serum levels of several MMPs and TIMPs in 43 relapsing-remitting MS (RRMS) patients undergoing interferon-beta (IFN-b) treatment and classified as responders and non-responders based on clinical criteria. Levels of MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 were determined by ELISA before treatment and after 3, 6, 12, and 24 months of therapy. Neutralizing antibodies were determined by the myxovirus A induction bioassay. Treatment with IFN-b induced changes in levels of MMP-9 and TIMP-1. In contrast to non-responders, IFN-b resulted in an early and sustained increase in TIMP-1 levels in MS patients who showed clinical response to IFN-b. The early and sustained increase in TIMP-1 levels could be a marker of the response to IFN-b during the first 2 years of treatment.
机译：基质金属蛋白酶（MMPs）和组织抑制剂（TIMPs）在多发性硬化症（MS）的发病机理中起关键作用，并已被提议作为对治疗反应的生物标记。我们调查了43位接受干扰素-β（IFN-b）治疗的复发-缓解型MS（RRMS）患者的几种MMP和TIMP的血清水平，并根据临床标准将其分为反应者和非反应者。在治疗前和治疗后3、6、12和24个月通过ELISA测定MMP-2，MMP-7，MMP-9，TIMP-1和TIMP-2的水平。通过粘病毒A诱导生物测定法测定中和抗体。用IFN-b治疗引起MMP-9和TIMP-1水平的变化。与无反应者相反，在临床表现出对IFN-b有反应的MS患者中，IFN-b导致TIMP-1水平的早期持续升高。在治疗的前两年，TIMP-1水平的早期持续升高可能是对IFN-b应答的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号